Towards antivirals against Chikungunya virus
Autor(es): Abdelnabi Rana, Neyts Johan, Delang Leen
Resumo: Chikungunya virus (CHIKV) has re-emerged in recent decades, causing major outbreaks of chikungunya fever in many parts of Africa - Asia, - since the end of 2013 also in Central - South America. Infections are usually associated with a low mortality rate, but can proceed into a painful chronic stage, during which patients may suffer from polyarthralgia - joint stiffness for weeks - even several years. There are no vaccines or antiviral drugs available for the prevention or treatment of CHIKV infections. Current therapy therefore consists solely of the administration of analgesics, antipyretics - anti-inflammatory agents to relieve symptoms. We here review molecules that have been reported to inhibit CHIKV replication, either as direct-acting antivirals, host-targeting drugs or those that act via a yet unknown mechanism. This article forms part of a symposium in Antiviral Research on Chikungunya discovers the New World.""
Palavras-Chave: Antiviral therapy; Arbidol; Chikungunya virus; Favipiravir; Monoclonal antibodies; Ribavirin
Imprenta: Antiviral Research, v. 121, p. 59-68, 2015
Identificador do objeto digital: 10.1016/j.antiviral.2015.06.017
Descritores: Chikungunya virus - Antibodies ; Chikungunya Virus - Virus ; Chikungunya virus - Vaccine ; Chikungunya virus - Chikungunya fever
Data de publicação: 2015
